Reports Outline Breast Cancer Study Results from University of Louisville (Abstract B020: Pan-RAS inhibitors to treat luminal B beast cancer).

Předmět:	BREAST cancer TRIPLE-negative breast cancer
Zdroj:	Women's Health Weekly; 2/23/2024, p703-703, 1p
Abstrakt:	A recent report from the University of Louisville discusses the potential use of pan-RAS inhibitors to treat luminal B breast cancer. Luminal B breast cancer is a subtype of breast cancer that is more dangerous and less responsive to current therapies. The researchers developed novel small molecules that bind to the RAS oncoprotein, which is commonly hyper-activated in luminal B tumors. They validated the effectiveness of these agents in vitro and in vivo, suggesting that anti-RAS therapy may be a promising approach for treating luminal B breast cancer. The full report can be accessed for free through the American Association for Cancer Research. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu